COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

33 34 Next >

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD ↗

May 30, 2023

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for...

Via Benzinga

Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session ↗

May 26, 2023

Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support...

Via Benzinga

Link Between Cancer And Psilocybin: Research On This Palliative Promise ↗

May 22, 2023

The use of psychedelic-assisted therapy to treat cancer-related conditions has come a long way.

Via Benzinga

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗

May 15, 2023

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...

Via Benzinga

Expert Ratings for Compass Pathways ↗

May 11, 2023

Via Benzinga

Compass Pathways: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Earnings Preview: Compass Pathways ↗

May 10, 2023

Via Benzinga

COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials ↗

May 11, 2023

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent...

Via Benzinga

Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials ↗

May 11, 2023

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated...

Via Benzinga

Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript ↗

May 11, 2023

CMPS earnings call for the period ending March 31, 2023.

Via The Motley Fool

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

May 11, 2023

From COMPASS Pathways

Via GlobeNewswire

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why ↗

May 06, 2023

Another piece of the regulatory puzzle fell into place, but there are plenty more.

Via The Motley Fool

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations ↗

May 02, 2023

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS...

Via Benzinga

American Medical Association to Issue First New Code for Psychedelic Therapies

May 02, 2023

COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved

From COMPASS Pathways

Via GlobeNewswire

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗

April 21, 2023

Via Benzinga

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗

April 20, 2023

Via Benzinga

After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy? ↗

April 20, 2023

Atai's stock is hurting, but its pipeline is still packed with promising programs.

Via The Motley Fool

Cybin, Mind Medicine Among Top Psychedelic Movers Of Today ↗

April 19, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 18, 2023 ↗

April 18, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 17, 2023 ↗

April 17, 2023

Via Benzinga

5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More ↗

April 17, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the...

Via Benzinga

Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder ↗

April 14, 2023

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published...

Via Benzinga

ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

April 14, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 13, 2023 ↗

April 13, 2023

Via Benzinga

EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics ↗

April 13, 2023

The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.

Via Benzinga

Psychedelic Stock Gainers And Losers From April 12, 2023 ↗

April 12, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 11, 2023 ↗

April 11, 2023

Via Benzinga

Psychedelic Stock Gainers And Losers From April 10, 2023 ↗

April 10, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.